Daily reports from ASCO 2018 by Springer Healthcare
Daily reports from the first four days of ASCO 2018, the largest clinical oncology conference in the world. Read about some of the most important information released during the conference. Read more
-
PDFJun 05, 2018 | Lung Cancer ASCO 2018 Lung Cancer
-
PDFJun 05, 2018 | Lung Cancer ASCO 2018 Lung Cancer
IMpower131: Primary PFS and Safety Analysis of a Randomized Phase III Study of ▼Atezolizumab + Carboplatin + Paclitaxel or Nab-Paclitaxel Vs Carboplatin + Nab-Paclitaxel as 1L Therapy in Advanced Squamous NSCLC
-
PDFJun 02, 2018 | Lung Cancer ASCO 2018 Lung Cancer
Safety and clinical activity results from a Phase 1b study of ▼alectinib plus ▼atezolizumab in ALK+ advanced NSCLC
-
PDFJun 03, 2018 | Renal Cell Carcinoma ASCO 2018 Renal Cell Carcinoma
Patient-Reported Outcomes in IMmotion151: ▼Atezolizumab Plus Bevacizumab vs Sunitinib in Treatment-Naive Metastatic Renal Cell Carcinoma
-
PDFJun 03, 2018 | Oncology ASCO 2018 Oncology
Randomized phase 2 trial of polatuzumab vedotin with bendamustine and ▼rituximab in relapsed/refractory FL and DLBCL
-
PDFJun 04, 2018 | Oncology ASCO 2018 Oncology
High, durable minimal residual disease (MRD) negativity with ▼venetoclax + rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from the phase 3 MURANO study
-
PDFJun 05, 2018 | Breast Cancer ASCO 2018 Breast Cancer
Overall survival update of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib + paclitaxel for locally advanced/metastatic triple-negative breast cancer
-
PDFJun 05, 2018 | Breast Cancer ASCO 2018 Breast Cancer
Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER
-
PDFJun 07, 2018 | Lung Cancer ASCO 2018 Lung Cancer
Prospective Clinical Evaluation of Blood-Based Tumor Mutational Burden as a Predictive Biomarker for ▼Atezolizumab in 1L NSCLC: Interim B-F1RST Results
-
PDFJun 06, 2018 | Lung Cancer ASCO 2018 Lung Cancer
Application of a real world endpoint to identify and characterize genetic profiles of patients with poor prognosis in advanced non-small-cell lung cancer (aNSCLC)
-
PDFJun 07, 2018 | Lung Cancer ASCO 2018 Lung Cancer
Association of High Tissue Tumor Mutational Burden (TMB) and ▼Atezolizumab Efficacy Across Multiple Tumor Types
-
PDFMar 25, 2019 | Lung Cancer ASCO 2018 Lung Cancer
ASCO 2018 Oral presentation: Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026
-
PDFMar 25, 2019 | Lung Cancer ASCO 2018 Lung Cancer
ASCO 2018 Oral presentation: Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): Survival follow-up results of JO25567
-
PDFJun 02, 2018 | Solid TumoursPDFASCO 2018 Solid Tumours
Phase 1 study of Entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors
Jun 02, 2018 | Solid Tumours
Solid Tumours
Entrectinib (RXDX-101) is a potent, and selective inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK. From phase 1 and 2 trials in adults, entrectinib demonstrated efficacy in patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions. In this study we investigated entrectinib in children/adolescents with relapsed/refractory solid tumors. -
PDFJun 02, 2018 | Breast CancerPDFASCO 2018 Breast Cancer
IPATunity130: a pivotal randomized phase III trial evaluating ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered advanced triple-negative or hormone receptor-positive HER2-negative breast cancer
Jun 02, 2018 | Breast Cancer
Breast Cancer
The pivotal randomized phase III IPATunity130 trial aims to confirm and build on findings from LOTUS. The trial includes patients with either TNBC or hormone receptor-positive/HER2-negative (HR+/HER2–) PIK3CA/AKT1/PTEN-altered tumors. -
PDFJun 02, 2018 | Breast CancerPDFASCO 2018 Breast Cancer
IMpassion132: a double-blind randomized phase III trial evaluating chemotherapy with or without ▼atezolizumab for early progressing locally advanced/metastatic triple-negative breast cancer
Jun 02, 2018 | Breast Cancer
Breast Cancer
IMpassion132 (NCT03371017) is comparing atezolizumab plus chemotherapy versus placebo plus chemotherapy in patients with PD ≤12 months after completing chemotherapy for early breast cancer, and combines atezolizumab with two commonly used non-taxane chemotherapy regimens. ▼atezolizumab: This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Please see safety reporting on the contact us page via the site menu -
PDFJun 01, 2018 | Breast Cancer ASCO 2018 Breast Cancer
Final overall survival (OS) analysis of PHEREXA: A randomized phase III trial of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy
-
PDFJun 02, 2018 | Breast CancerPDFASCO 2018 Breast Cancer
Real-world (RW) characteristics, treatment (tx) patterns, and overall survival (OS) in US patients (pts) with metastatic breast cancer (MBC) and CNS metastases (CNS mets)
Jun 02, 2018 | Breast Cancer
Breast Cancer
There are limited clinical data on the outcomes of patients with breast cancer and central nervous system (CNS) metastases, due to limitations on enrollment criteria in clinical studies. Real-world data may provide complementary evidence to clinical studies regarding the characteristics, treatment, and outcomes of patients with metastatic breast cancer (MBC) and CNS metastases. This retrospective cohort analysis, conducted using Flatiron Health’s database (derived from patient-level electronic health records), describes the incidence of CNS metastases among patients with metastatic breast cancer, and patient characteristics at the time of MBC diagnosis, systemic drug therapy use, and overall survival after CNS metastases in the sub-population of patients with MBC diagnosed with CNS metastases. -
PDFJun 02, 2018 | Breast CancerPDFASCO 2018 Breast Cancer
Patient (pt)-reported function and symptoms in APHINITY: A randomized comparison of chemotherapy (C) + trastuzumab (H) + placebo (Pla) versus C + H + pertuzumab (P) as adjuvant therapy in pts with HER2-positive early breast cancer (EBC)
Jun 02, 2018 | Breast Cancer
Breast Cancer
The results of the patient-reported HRQoL secondary endpoints in APHINITY, which were defined as symptoms of therapy, patient functioning, and global health status. -
PDFJun 02, 2018 | Genitourinary CancerPDFASCO 2018 Genitourinary Cancer
▼Atezolizumab (Atezo) in Special Populations: Analyses From an Expanded Access Program (EAP) in Platinum-Treated Locally Advanced or Metastatic Urothelial Carcinoma (mUC)
Jun 02, 2018 | Genitourinary Cancer
Genitourinary Cancer
This poster presents clinical outcomes in special populations from an expanded access study of atezolizumab in platinum-treated metastatic urothelial carcinoma. Subgroups evaluated include patients with impaired baseline renal function or variant histology. The impacts of such clinical features on efficacy and safety outcomes are described. ▼Atezolizumab: This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Please see safety reporting on the contact us page via the site menu -
PDFJun 02, 2018 | Genitourinary CancerPDFASCO 2018 Genitourinary Cancer
▼Atezolizumab in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer: long-term efficacy from Ph II study IMvigor210
Jun 02, 2018 | Genitourinary Cancer
Genitourinary Cancer
This poster presents a long-term clinical update from the Phase II IMvigor210 study (atezolizumab in metastatic urothelial carcinoma), both in previously untreated cisplatin-ineligible patients (cohort 1) and in previously platinum-treated patients (cohort 2). Similarities and differences with respect to prior analyses are presented (e.g., updates in mOS, mDOR). Subgroup analyses and characterization of outcomes in elderly Cohort 1 patients are also reported. ▼Atezolizumab: This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Please see safety reporting on the contact us page via the site menu -
PDFJun 06, 2018 | Lung CancerPDFASCO 2018 Lung Cancer
Updated efficacy and safety data from the global phase III ALEX study of ▼alectinib (AL) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC
Jun 06, 2018 | Lung Cancer
Lung Cancer
At the primary analysis (data cut-off, 9 February 2017) alectinib showed superior investigator-assessed PFS vs crizotinib in patients with untreated ALK+ NSCLC. The safety profile of alectinib also compared favourably with crizotinib. This publication presents updated efficacy and safety data (cut-off 1 Dec 2017, with a median follow up time of 27.8 months). ▼Alectinib: This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Please see safety reporting on the contact us page via the site menu. -
PDFJun 03, 2018 | Lung CancerPDFASCO 2018 Lung Cancer
Pooled Overall Survival and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of ▼Alectinib in ALK-positive Non-Small Cell Lung Cancer (NSCLC)
Jun 03, 2018 | Lung Cancer
Lung Cancer
Alectinib, a highly selective inhibitor of ALK tyrosine kinase, has demonstrated systemic and central nervous system activity in ALK+ NSCLC. Two single-arm, open-label phase II studies (NP28673; global [NCT01801111] and NP28761; North American [NCT01871805]) have previously demonstrated robust overall survival (OS) in crizotinib-resistant ALK+ NSCLC (Yang et al, J Thorac Oncol 2017). We report final pooled phase II OS and safety data after a longer duration of follow-up. ▼Alectinib: This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Please see safety reporting on the contact us page via the site menu. -
PDFJun 03, 2018 | Lung CancerPDFASCO 2018 Lung Cancer
Patient-reported outcomes in the randomized, Phase III IMpower150 study of ▼atezolizumab + chemotherapy ± bevacizumab vs chemotherapy + bevacizumab in 1L nonsquamous metastatic NSCLC
Jun 03, 2018 | Lung Cancer
Lung Cancer
The patient-reported outcomes from the randomised, Phase III IMpower150 study investigating the combination of atezolizumab + chemotherapy ± bevacizumab versus chemotherapy + bevacizumab in 1L nonsquamous NSCLC are reported. IMpower150 has shown statistically significant and clinically meaningful progression-free survival and overall survival benefit for patients with atezolizumab + chemotherapy + bevacizumab versus chemotherapy + bevacizumab. This combination has also demonstrated a manageable safety profile with no new safety risks. The objective of this poster was to determine the relative impact of the addition of atezolizumab to chemotherapy ± bevacizumab on patient-reported health-related quality of life, physical functioning, and treatment-related and lung cancer-related symptom burden in the IMpower150 study. ▼atezolizumab: This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Please see safety reporting on the contact us page via the site menu. -
PDFJun 03, 2018 | Lung CancerPDFASCO 2018 Lung Cancer
Neoadjuvant ▼Atezolizumab in Resectable Non-Small Cell Lung Cancer: Interim Analysis Results From of a Multicenter Study (LCMC3)
Jun 03, 2018 | Lung Cancer
Lung Cancer
The multi-center Phase II study LCMC3 evaluates neoadjuvant and adjuvant PD-L1 inhibition with atezolizumab in patients with resectable non-small cell lung cancer. This poster presents the results of a protocol-specified interim safety analysis. ▼Atezolizumab: This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Please see safety reporting on the contact us page via the site menu. -
PDFJun 03, 2018 | Lung CancerPDFASCO 2018 Lung Cancer
MORPHEUS: a Phase Ib/II Multi-Trial Platform Evaluating the Safety and Efficacy of Cancer Immunotherapy–Based Combinations in Patients With Non-Small Cell Lung Cancer (MORPHEUS-Lung)
Jun 03, 2018 | Lung Cancer
Lung Cancer
The MORPHEUS platform consists of multiple Phase Ib/II trials designed to identify early signals and establish proof-of-concept clinical data to support the development of CIT combinations in several indications. This TiP poster presents the study design, eligibility criteria and endpoints for the MORPHEUS-Lung study, which will enroll two cohorts of patients with advanced unresectable or metastatic non-small cell lung cancer (NSCLC). -
PDFJun 03, 2018 | Gastrointestinal CancerPDFASCO 2018 Gastrointestinal Cancer
Safety and Clinical Activity of ▼Atezolizumab + Bevacizumab in a Phase Ib Study in First-Line Hepatocellular Carcinoma
Jun 03, 2018 | Gastrointestinal Cancer
Gastrointestinal Cancer
Hepatocellular carcinoma (HCC) is a lethal disease with limited treatment options. Here we report the results from a Phase Ib study of atezolizumab (anti–PD-L1) + bevacizumab (anti-VEGF) in patients with previously untreated, unresectable or metastatic HCC. The safety and clinical activity data from the ITT population and key patient subgroups will be presented. ▼Atezolizumab : This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Please see safety reporting on the contact us page via the site menu -
PDFJun 03, 2018 | Gastrointestinal CancerPDFASCO 2018 Gastrointestinal Cancer
MORPHEUS: a Phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy combinations in patients with gastric or pancreatic cancer
Jun 03, 2018 | Gastrointestinal Cancer
Gastrointestinal Cancer
The MORPHEUS platform consists of multiple Phase Ib/II trials and aims to identify early signals and establish proof-of-concept clinical data to support the development of cancer immunotherapy combinations in several indications. This Trial in Progress poster presents the study design, eligibility criteria, endpoints and enrollment sites for the MORPHEUS-GC and MORPHEUS-PDAC studies, which will enroll patients with advanced unresectable or metastatic gastric cancer (GC) or metastatic pancreatic ductal adenocarcinoma (PDAC), respectively. -
PDFJun 03, 2018 | Gastrointestinal CancerPDFASCO 2018 Gastrointestinal Cancer
IMbrave150: a randomized Phase III study of 1L ▼atezolizumab plus bevacizumab vs sorafenib in 1L Locally advanced or metastatic hepatocellular carcinoma
Jun 03, 2018 | Gastrointestinal Cancer
Gastrointestinal Cancer
IMbrave150 is a randomized Phase III study that investigates the effects of atezolizumab (anti–PD-L1) + bevacizumab (anti–VEGF) combination therapy vs sorafenib in first-line hepatocellular carcinoma (HCC). It will enroll patients with locally advanced or metastatic and/or unresectable HCC. This Trial in Progress poster presents study design, eligibility criteria, endpoints and enrollment sites of the study. ▼Atezolizumab: This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Please see safety reporting on the contact us page via the site menu. -
PDFJun 04, 2018 | Skin CancerPDFASCO 2018 Skin Cancer
Efficacy and safety of ▼cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study
Jun 04, 2018 | Skin Cancer
Skin Cancer
Resistance to BRAF inhibitor monotherapy in BRAFV600-mutated metastatic melanoma limits PFS benefit and is most commonly the result of the paradoxical reactivation of mitogen-activated protein kinase (MAPK) pathway through MEK. The randomized phase 3 coBRIM trial (GO28141) showed that combining the MEK inhibitor cobimetinib with vemurafenib provided a statistically significant and clinically meaningful improvement in PFS and OS versus vemurafenib therapy alone. Extended follow-up of the phase 3 coBRIM study would provide useful clinical insight regarding the long-term efficacy and safety of cobimetinib plus vemurafenib for patients with BRAFV600-mutated metastatic melanoma. This poster presents the long-term efficacy and safety data from patients enrolled in the coBRIM phase 3 study after 4 years of follow-up (data cutoff date, October 13, 2017) ▼Cobimetinib: This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Please see safety reporting on the contact us page via the site menu. -
PDFJun 04, 2018 | Gastrointestinal CancerPDFASCO 2018 Gastrointestinal Cancer
Pharmacokinetic (PK) and exposure–response (ER) analysis of pertuzumab in patients with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC)
Jun 04, 2018 | Gastrointestinal Cancer
Gastrointestinal Cancer
The phase III JACOB study evaluated the efficacy and safety of intravenous pertuzumab plus trastuzumab and chemotherapy, compared with placebo plus trastuzumab and chemotherapy as a first-line treatment in patients with HER2-positive metastatic gastroesophageal junction cancer or gastric cancer. Pharmacokinetic (PK) samples were collected from all patients who participated in JACOB to assess the PK of pertuzumab, trastuzumab and chemotherapy. Here we report the PK, drug-drug interaction, and exposure-response analyses from the JACOB study. -
PDFJun 04, 2018 | Cervical CancerPDFASCO 2018 Cervical Cancer
Preliminary results from CECILIA, an open-label global safety study of bevacizumab, carboplatin, and paclitaxel therapy for metastatic, recurrent, or persistent cervical cancer
Jun 04, 2018 | Cervical Cancer
Cervical Cancer
Preliminary results from the open-label single-arm CECILIA study after all patients had been followed for at least 6 months. -
PDFJun 04, 2018 | OncologyPDFASCO 2018 Oncology
Relationship between MRD and PET responses and PFS in previously untreated follicular lymphoma in the GALLIUM trial
Jun 04, 2018 | Oncology
Oncology
This analysis assessed the relationship between end of induction (EOI) MRD and PET responses in the phase III GALLIUM study and the prognostic implication for PFS in previously untreated patients with follicular lymphoma (FL). -
PDFJun 04, 2018 | OncologyPDFASCO 2018 Oncology
A phase 3 study comparing polatuzumab vedotin plus R-CHP versus R-CHOP in patients with DLBCL (POLARIX)
Jun 04, 2018 | Oncology
Oncology
POLARIX is a multicentre, randomized, double-blind, placebo-controlled phase III study in patients with previously untreated DLBCL; this trial-in-progress presentation reports the study design and endpoints. Patients will be randomized 1:1 (stratified by IPI score [2 versus 3–5], bulky disease and geographical region) to receive pola 1.8 mg/kg on Day 1 plus R-CHP (standard dosing schedule) plus vincristine placebo for 6 cycles, or R-CHOP (standard dosing schedule) with pola placebo for 6 cycles. The primary endpoint is investigator- assessed PFS using Lugano classification. Secondary endpoints include PET-CT complete response rate at end of treatment assessed by an independent review committee, event-free survival due to efficacy reason, 2-year PFS rate, and OS. Enrolment began November 2015 and patient follow-up will continue for 5 years after end of treatment. -
PDFJun 02, 2018 | Lung CancerPDFASCO 2018 Lung Cancer
Real-world data on tumor response in patients with advanced non-small-cell lung cancer receiving cancer immunotherapy or targeted therapies
Jun 02, 2018 | Lung Cancer
Lung Cancer
Overall response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) is an established early efficacy endpoint used in clinical trials. Comparison of real world tumor response (rwTR) and ORR can provide important insights for health professionals, regulators, and researchers. -
PDFJun 02, 2018 | Lung CancerPDFASCO 2018 Lung Cancer
Are NCCN Evidence Block Affordability Ratings Representative of Real-World Costs? An Evaluation of Advanced Non-Small Cell Lung Cancer (aNSCLC)
Jun 02, 2018 | Lung Cancer
Lung Cancer
The NCCN evidence blocks are designed to provide affordability ratings on the overall cost of drug treatments (tx), including medication, administration, supportive care, side-effect management and hospitalization. This study characterized the relationship between real-world costs of aNSCLC tx and NCCN affordability rating.